USRE37650E1
(en)
|
1991-05-10 |
2002-04-09 |
Aventis Pharmacetical Products, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US5721237A
(en)
*
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
US5710158A
(en)
*
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
ES2108120T3
(es)
*
|
1991-05-10 |
1997-12-16 |
Rhone Poulenc Rorer Int |
Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
|
US5480883A
(en)
*
|
1991-05-10 |
1996-01-02 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5714493A
(en)
*
|
1991-05-10 |
1998-02-03 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US6645969B1
(en)
|
1991-05-10 |
2003-11-11 |
Aventis Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
GB9121943D0
(en)
*
|
1991-10-16 |
1991-11-27 |
Sandoz Ltd |
Organic compounds,processes for their production and their use
|
AU661533B2
(en)
*
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5981569A
(en)
*
|
1992-11-13 |
1999-11-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
|
US5763441A
(en)
*
|
1992-11-13 |
1998-06-09 |
Sugen, Inc. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5712395A
(en)
*
|
1992-11-13 |
1998-01-27 |
Yissum Research Development Corp. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5792771A
(en)
*
|
1992-11-13 |
1998-08-11 |
Sugen, Inc. |
Quinazoline compounds and compositions thereof for the treatment of disease
|
GB9323290D0
(en)
*
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
US5409886A
(en)
*
|
1993-02-18 |
1995-04-25 |
Mitsui Toatsu Chemicals, Incorporated |
3-pyrroline-2-one derivatives and herbicidal compositions containing same
|
US5451603A
(en)
*
|
1993-03-11 |
1995-09-19 |
Zymogenetics, Inc. |
3,4-diarylchromans for treatment of dermatitis
|
GB9314893D0
(en)
*
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9325217D0
(en)
*
|
1993-12-09 |
1994-02-09 |
Zeneca Ltd |
Pyrimidine derivatives
|
US5416098A
(en)
*
|
1993-12-30 |
1995-05-16 |
Zymogenetics, Inc. |
Method for treating dermatitis and related conditions
|
US5700823A
(en)
*
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
IL112248A0
(en)
*
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
CZ288955B6
(cs)
*
|
1994-02-23 |
2001-10-17 |
Pfizer Inc. |
Substituované chinazolinové deriváty, jejich pouľití a farmaceutické prostředky na jejich bázi
|
WO1995024190A2
(en)
*
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
US5578609A
(en)
*
|
1994-03-25 |
1996-11-26 |
The Dupont Merck Pharmaceutical Company |
2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
|
US5523408A
(en)
*
|
1994-03-25 |
1996-06-04 |
The Dupont Merck Pharmaceutical Company |
2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
|
ES2109796T3
(es)
*
|
1994-05-03 |
1998-01-16 |
Ciba Geigy Ag |
Derivados de pirrolopirimidilo con efecto antiproliferante.
|
GB9514160D0
(en)
*
|
1994-07-25 |
1995-09-13 |
Zeneca Ltd |
Aromatic compounds
|
GB9417532D0
(en)
*
|
1994-08-31 |
1994-10-19 |
Zeneca Ltd |
Aromatic compounds
|
US5476851A
(en)
*
|
1994-09-08 |
1995-12-19 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
|
US5804396A
(en)
*
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
GB9420557D0
(en)
*
|
1994-10-12 |
1994-11-30 |
Zeneca Ltd |
Aromatic compounds
|
AU700964B2
(en)
*
|
1994-11-10 |
1999-01-14 |
Cor Therapeutics, Inc. |
Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
|
TW321649B
(de)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
IL115256A0
(en)
*
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
US6562854B2
(en)
|
1994-12-14 |
2003-05-13 |
Axys Pharmaceuticals, Inc. |
Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
|
CA2214131C
(en)
*
|
1995-03-14 |
2009-06-23 |
Novartis Ag |
Trisubstituted phenyl derivatives
|
WO1996030347A1
(en)
|
1995-03-30 |
1996-10-03 |
Pfizer Inc. |
Quinazoline derivatives
|
ES2150113T3
(es)
*
|
1995-04-03 |
2000-11-16 |
Novartis Ag |
Derivados de pirazol y procedimientos para la preparacion de los mismos.
|
US5721277A
(en)
*
|
1995-04-21 |
1998-02-24 |
Sugen, Inc. |
Compounds and methods for inhibiting hyper-proliferative cell growth
|
JPH11507329A
(ja)
*
|
1995-04-27 |
1999-06-29 |
ゼネカ リミテッド |
キナゾリン誘導体
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
US5620981A
(en)
*
|
1995-05-03 |
1997-04-15 |
Warner-Lambert Company |
Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
|
IL117923A
(en)
*
|
1995-05-03 |
2000-06-01 |
Warner Lambert Co |
Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
US5747498A
(en)
*
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US6147106A
(en)
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US5773459A
(en)
*
|
1995-06-07 |
1998-06-30 |
Sugen, Inc. |
Urea- and thiourea-type compounds
|
US5880141A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
AU6112896A
(en)
*
|
1995-06-07 |
1996-12-30 |
Sugen, Inc. |
Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders
|
JPH11507052A
(ja)
*
|
1995-06-07 |
1999-06-22 |
スージェン・インコーポレーテッド |
キナゾリンおよび医薬組成物
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US5650415A
(en)
*
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
US5763470A
(en)
*
|
1995-06-07 |
1998-06-09 |
Sugen Inc. |
Benzopyran compounds and methods for their use
|
US5710173A
(en)
*
|
1995-06-07 |
1998-01-20 |
Sugen, Inc. |
Thienyl compounds for inhibition of cell proliferative disorders
|
TW434240B
(en)
*
|
1995-06-20 |
2001-05-16 |
Zeneca Ltd |
Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
|
TW502026B
(en)
*
|
1995-06-20 |
2002-09-11 |
Zeneca Ltd |
Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
|
TR199800012T1
(xx)
*
|
1995-07-06 |
1998-04-21 |
Novartis Ag |
Piroloprimidinler ve preparasyon i�in tatbikler.
|
DE69635254T2
(de)
*
|
1995-07-07 |
2006-07-13 |
Astrazeneca Ab |
Ortho-substituierte aromatische Verbindungen, die drei (Het)aryl-Ringe enthalten, deren Herstellung und deren Verwendung als Prostaglandin-E2-(PGE2)-Antagonisten
|
DE69637587D1
(de)
*
|
1995-07-26 |
2008-08-21 |
Astrazeneca Ab |
Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
|
EP0788353A1
(de)
|
1995-09-18 |
1997-08-13 |
Ligand Pharmaceuticals, Inc. |
Ppar gamma antagonisten zur behandlung der fettleibigkeit
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
US7119174B2
(en)
|
1995-12-18 |
2006-10-10 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
US6716575B2
(en)
|
1995-12-18 |
2004-04-06 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
AU719434B2
(en)
|
1996-02-13 |
2000-05-11 |
Astrazeneca Ab |
Quinazoline derivatives as VEGF inhibitors
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
CA2244897C
(en)
|
1996-03-05 |
2006-04-11 |
Zeneca Limited |
4-anilinoquinazoline derivatives
|
ATE298739T1
(de)
|
1996-04-09 |
2005-07-15 |
Nps Pharma Inc |
Calcylitische verbindungen
|
US6818660B2
(en)
|
1996-04-09 |
2004-11-16 |
Nps Pharmaceuticals, Inc. |
Calcilytic compounds
|
BR9708640B1
(pt)
|
1996-04-12 |
2013-06-11 |
|
inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo.
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
US6297198B1
(en)
|
1996-05-14 |
2001-10-02 |
Syngenta Participations Ag |
Isoxazole derivatives and their use as herbicides
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
US6124289A
(en)
*
|
1996-07-24 |
2000-09-26 |
Dupont Pharmaceuticals Co. |
Azolo triazines and pyrimidines
|
US7094782B1
(en)
|
1996-07-24 |
2006-08-22 |
Bristol-Myers Squibb Company |
Azolo triazines and pyrimidines
|
US6313124B1
(en)
|
1997-07-23 |
2001-11-06 |
Dupont Pharmaceuticals Company |
Tetrazine bicyclic compounds
|
US6060478A
(en)
*
|
1996-07-24 |
2000-05-09 |
Dupont Pharmaceuticals |
Azolo triazines and pyrimidines
|
US6191131B1
(en)
|
1997-07-23 |
2001-02-20 |
Dupont Pharmaceuticals Company |
Azolo triazines and pyrimidines
|
JP3243733B2
(ja)
*
|
1996-08-07 |
2002-01-07 |
雪印乳業株式会社 |
新規イソキノリン誘導体
|
US6682921B1
(en)
|
1996-08-21 |
2004-01-27 |
New York University |
Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
|
DE69738468T2
(de)
|
1996-08-23 |
2009-01-08 |
Novartis Ag |
Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
|
US6004967A
(en)
*
|
1996-09-13 |
1999-12-21 |
Sugen, Inc. |
Psoriasis treatment with quinazoline compounds
|
GB9718972D0
(en)
*
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
CN1252054C
(zh)
|
1996-09-25 |
2006-04-19 |
曾尼卡有限公司 |
抑制生长因子的作用的喹啉衍生物
|
CA2239227C
(en)
*
|
1996-10-01 |
2007-10-30 |
Kenji Matsuno |
Nitrogen-containing heterocyclic compounds
|
WO1998014450A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
US5827898A
(en)
*
|
1996-10-07 |
1998-10-27 |
Shaman Pharmaceuticals, Inc. |
Use of bisphenolic compounds to treat type II diabetes
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
EP0837063A1
(de)
*
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazolinderivate
|
US7202261B2
(en)
|
1996-12-03 |
2007-04-10 |
Nps Pharmaceuticals, Inc. |
Calcilytic compounds
|
TW483881B
(en)
|
1996-12-03 |
2002-04-21 |
Nps Pharma Inc |
Calcilytic compounds
|
EP1806348A3
(de)
*
|
1997-02-05 |
2008-01-02 |
Warner-Lambert Company LLC |
Pyrido (2,3-D)Pyrimidine als Inhibitoren der zellulären Proliferation
|
US6498163B1
(en)
|
1997-02-05 |
2002-12-24 |
Warner-Lambert Company |
Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
EP0964864B1
(de)
*
|
1997-02-05 |
2008-04-09 |
Warner-Lambert Company LLC |
Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
|
US6818440B2
(en)
|
1997-04-28 |
2004-11-16 |
Sugen, Inc. |
Diagnosis and treatment of alk-7 related disorders
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
US6316479B1
(en)
|
1997-05-19 |
2001-11-13 |
Sugen, Inc. |
Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
|
US6228641B1
(en)
|
1997-05-20 |
2001-05-08 |
Sugen, Inc. |
Diagnosis and treatment of PTP04 related disorders
|
CA2291750A1
(en)
*
|
1997-05-28 |
1998-12-03 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
US6180632B1
(en)
*
|
1997-05-28 |
2001-01-30 |
Aventis Pharmaceuticals Products Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
US6159978A
(en)
*
|
1997-05-28 |
2000-12-12 |
Aventis Pharmaceuticals Product, Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
US6245760B1
(en)
*
|
1997-05-28 |
2001-06-12 |
Aventis Pharmaceuticals Products, Inc |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
US6342593B1
(en)
|
1997-06-11 |
2002-01-29 |
Sugen, Inc. |
Diagnosis and treatment of ALP related disorders
|
US7115710B2
(en)
|
1997-06-11 |
2006-10-03 |
Sugen, Inc. |
Diagnosis and treatment of PTP related disorders
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US6388063B1
(en)
|
1997-06-18 |
2002-05-14 |
Sugen, Inc. |
Diagnosis and treatment of SAD related disorders
|
US6103905A
(en)
*
|
1997-06-19 |
2000-08-15 |
Sepracor, Inc. |
Quinoline-indole antimicrobial agents, uses and compositions related thereto
|
US6376670B1
(en)
|
1997-06-19 |
2002-04-23 |
Sepracor Inc. |
Quinoline-indole antimicrobial agents, uses and compositions related thereto
|
KR20010014030A
(ko)
|
1997-06-19 |
2001-02-26 |
더글라스이.리디치 |
퀴놀린-인돌 항균제, 이들의 용도 및 조성물
|
US6207679B1
(en)
|
1997-06-19 |
2001-03-27 |
Sepracor, Inc. |
Antimicrobial agents uses and compositions related thereto
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
US6051593A
(en)
*
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
US6130238A
(en)
*
|
1997-06-20 |
2000-10-10 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
US7098025B1
(en)
|
1997-07-25 |
2006-08-29 |
Ligand Pharmaceuticals Incorporated |
Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
|
US6329375B1
(en)
|
1997-08-05 |
2001-12-11 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
US6150359A
(en)
*
|
1997-08-20 |
2000-11-21 |
Warner-Lambert Company |
Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
|
US6294532B1
(en)
|
1997-08-22 |
2001-09-25 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
DE69827516T2
(de)
*
|
1997-09-26 |
2005-12-01 |
Zentaris Gmbh |
Azabenzimidazol-verbindungen zur modulation der serin/threonin protein-kinase funktion
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
CA2304466A1
(en)
|
1997-10-06 |
1999-04-15 |
Basf Aktiengesellschaft |
Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
|
AU9691198A
(en)
*
|
1997-10-06 |
1999-04-27 |
Basf Aktiengesellschaft |
Indeno{1,2-c}-, naphtho{1,2-c}- and benzo{6,7}cyclohepta{1,2-c}pyrazole derivatives
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
US6225346B1
(en)
|
1997-10-24 |
2001-05-01 |
Sugen, Inc. |
Tyrphostin like compounds
|
EP1215208B1
(de)
*
|
1997-10-27 |
2006-07-12 |
Agouron Pharmaceuticals, Inc. |
4-Aminothiazol Derivate, deren Herstellung und deren Verwendung als Inhibitoren Cyclin-abhängiger Kinasen
|
KR20010082501A
(ko)
*
|
1997-10-27 |
2001-08-30 |
개리 이. 프라이드만 |
4-아미노티아졸 유도체, 그 제조방법 및 싸이클린-의존성키나아제의 억제제로서의 이용방법
|
US6150379A
(en)
*
|
1997-11-26 |
2000-11-21 |
Axys Pharmaceuticals, Inc. |
Compounds and compositions as anticoagulants
|
US5932580A
(en)
*
|
1997-12-01 |
1999-08-03 |
Yissum Research And Development Company Of The Hebrew University Of Jerusalem |
PDGF receptor kinase inhibitory compounds their preparation and compositions
|
DK0924209T3
(da)
*
|
1997-12-19 |
2003-08-25 |
Lilly Co Eli |
Hypoglykæmiske imidazolinforbindelser
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
CA2318403A1
(en)
|
1998-01-21 |
1999-07-29 |
Sugen, Inc. |
Human orthologues of wart
|
US6756367B2
(en)
*
|
1998-02-03 |
2004-06-29 |
Novartis Ag |
Benzo-oxadiazoles, -thiadiazoles and -1,4-diazines, pharmaceutical compositions containing them and a process for preparing them
|
JP2002507598A
(ja)
*
|
1998-03-26 |
2002-03-12 |
スージェン・インコーポレーテッド |
チロシン蛋白質キナーゼを調節するためのヘテロ環式化合物のファミリー
|
CA2326324C
(en)
|
1998-03-31 |
2010-05-11 |
Kyowa Hakko Kogyo Co., Ltd. |
Nitrogen-containing heterocyclic compound
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
WO1999052895A1
(en)
|
1998-04-10 |
1999-10-21 |
Japan Tobacco Inc. |
Amidine compounds
|
DE69926742T2
(de)
|
1998-04-14 |
2006-06-14 |
Sugen Inc |
Ste20-verwandte proteinkinasen
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
EP1801112A1
(de)
*
|
1998-05-26 |
2007-06-27 |
Warner-Lambert Company LLC |
Bizyklische Pyrimidine und bizyklische 3,4-Dihydropyrimidine als Hemmer der Zellvermehrung
|
ES2310039T3
(es)
*
|
1998-05-26 |
2008-12-16 |
Warner-Lambert Company Llc |
Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.
|
EP1082305A4
(de)
|
1998-05-29 |
2001-09-26 |
Sugen Inc |
Pyrrol substituierte 2-indolinone wirksam als proteinkinase-hemmer
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
AP1411A
(en)
|
1998-06-02 |
2005-05-10 |
Osi Pharm Inc |
Pyrrolo[2,3d] pyrimidine compositions and their use.
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
CA2334545A1
(en)
*
|
1998-06-12 |
1999-12-16 |
Ligand Pharmaceuticals Incorporated |
Treatment of anti-estrogen resistant breast cancer using rxr modulators
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
ATE342892T1
(de)
|
1998-08-29 |
2006-11-15 |
Astrazeneca Ab |
Pyrimidine verbindungen
|
US6632820B1
(en)
|
1998-08-29 |
2003-10-14 |
Astrazeneca Ab |
Pyrimidine compounds
|
US6525072B1
(en)
|
1998-08-31 |
2003-02-25 |
Sugen, Inc. |
Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
|
WO2000014105A1
(en)
|
1998-09-08 |
2000-03-16 |
Agouron Pharmaceuticals, Inc. |
Modifications of the vegf receptor-2 protein and methods of use
|
US6680335B2
(en)
|
1998-09-28 |
2004-01-20 |
Sugen, Inc. |
Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
|
ES2241324T3
(es)
|
1998-10-08 |
2005-10-16 |
Astrazeneca Ab |
Derivados de quinazolina.
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
EP1630559A3
(de)
*
|
1998-12-30 |
2006-06-07 |
Sugen, Inc. |
PYK2 (RAFTK) und Entzündung
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
DK1154774T3
(da)
|
1999-02-10 |
2005-09-26 |
Astrazeneca Ab |
Quinazolinderivater som angiogenesisinhibitorer
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
UA71971C2
(en)
*
|
1999-06-04 |
2005-01-17 |
Agoron Pharmaceuticals Inc |
Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
CN1391561A
(zh)
|
1999-09-21 |
2003-01-15 |
阿斯特拉曾尼卡有限公司 |
喹唑啉化合物和含有喹唑啉化合物的药物组合物
|
ES2235970T3
(es)
*
|
1999-10-19 |
2005-07-16 |
MERCK & CO. INC. |
Inhibidores de tirosina quinasa.
|
US6794393B1
(en)
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
ES2234698T3
(es)
*
|
1999-10-19 |
2005-07-01 |
MERCK & CO., INC. |
Inhibidores de tirosina quinasa.
|
AU783082B2
(en)
|
1999-10-22 |
2005-09-22 |
Pharmacia & Upjohn Company |
Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
|
SI1676845T1
(sl)
|
1999-11-05 |
2008-10-31 |
Astrazeneca Ab |
Novi kinazolinski derivati
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
CO5261573A1
(es)
|
1999-11-19 |
2003-03-31 |
Novartis Ag |
Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
US7160890B2
(en)
*
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US20020010203A1
(en)
|
1999-12-22 |
2002-01-24 |
Ken Lipson |
Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
|
AU2001228638A1
(en)
|
2000-01-28 |
2001-08-07 |
Astrazeneca Ab |
Chemical compounds
|
WO2001057008A1
(en)
|
2000-02-07 |
2001-08-09 |
Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft |
2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
|
PT1255752E
(pt)
*
|
2000-02-15 |
2007-10-17 |
Pharmacia & Upjohn Co Llc |
Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
|
JP2003523390A
(ja)
*
|
2000-02-25 |
2003-08-05 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害薬
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US6420382B2
(en)
*
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
WO2001064681A2
(en)
|
2000-02-28 |
2001-09-07 |
Sugen, Inc. |
3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US6511984B2
(en)
|
2000-03-30 |
2003-01-28 |
Pfizer Inc. |
Neuropeptide Y antagonists
|
SI1274692T1
(sl)
|
2000-04-07 |
2006-12-31 |
Astrazeneca Ab |
Kinazolinske spojine
|
EP1274706A1
(de)
|
2000-04-18 |
2003-01-15 |
Agouron Pharmaceuticals, Inc. |
Pyrazole zur inhibierung von proteinkinasen
|
MY128450A
(en)
|
2000-05-24 |
2007-02-28 |
Upjohn Co |
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
US6706709B2
(en)
|
2000-06-02 |
2004-03-16 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
PE20020063A1
(es)
|
2000-06-20 |
2002-01-30 |
Upjohn Co |
Bis-arilsulfonas como ligandos del receptor de 5-ht
|
US6586592B2
(en)
|
2000-06-20 |
2003-07-01 |
Pharmacia & Upjohn Company |
Bis-arylsulfones
|
DE60133897D1
(de)
|
2000-06-28 |
2008-06-19 |
Astrazeneca Ab |
Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
IL153947A0
(en)
*
|
2000-08-09 |
2003-07-31 |
Astrazeneca Ab |
Quinoline derivatives having vegf inhibiting activity
|
AU2001276521B2
(en)
|
2000-08-09 |
2006-05-25 |
Astrazeneca Ab |
Cinnoline compounds
|
CN100358890C
(zh)
|
2000-08-18 |
2008-01-02 |
千年药物股份有限公司 |
喹唑啉衍生物类激酶抑制剂
|
BR0113358A
(pt)
|
2000-08-21 |
2003-07-01 |
Astrazeneca Ab |
Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
|
US6756383B2
(en)
|
2000-09-01 |
2004-06-29 |
Chiron Corporation |
Heterocyclic derivatives of quinolinone benimidazoles
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
MXPA03002032A
(es)
|
2000-09-11 |
2003-07-24 |
Chiron Corp |
Derivados de quinolinona.
|
FR2813791B1
(fr)
*
|
2000-09-14 |
2004-03-12 |
Lafon Labor |
Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
|
WO2002030924A1
(en)
|
2000-10-13 |
2002-04-18 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
US6939866B2
(en)
|
2000-10-13 |
2005-09-06 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6656942B2
(en)
|
2000-10-17 |
2003-12-02 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
ATE355275T1
(de)
|
2000-10-20 |
2006-03-15 |
Eisai R&D Man Co Ltd |
Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
|
CZ20031125A3
(cs)
*
|
2000-10-23 |
2003-10-15 |
Smithkline Beecham Corporation |
Nové sloučeniny
|
ATE502928T1
(de)
|
2000-11-01 |
2011-04-15 |
Millennium Pharm Inc |
Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
|
US7067532B2
(en)
*
|
2000-11-02 |
2006-06-27 |
Astrazeneca |
Substituted quinolines as antitumor agents
|
WO2002036570A1
(en)
*
|
2000-11-02 |
2002-05-10 |
Astrazeneca Ab |
4-substituted quinolines as antitumor agents
|
US6582919B2
(en)
|
2001-06-11 |
2003-06-24 |
Response Genetics, Inc. |
Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
|
US6680324B2
(en)
*
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
EP1381599B1
(de)
|
2001-04-19 |
2008-09-24 |
Astrazeneca AB |
Chinazolin derivate
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
PE20030062A1
(es)
|
2001-05-30 |
2003-02-08 |
Sugen Inc |
Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
US8124625B2
(en)
*
|
2001-09-14 |
2012-02-28 |
Shionogi & Co., Ltd. |
Method of enhancing the expression of apolipoprotein AI using olefin derivatives
|
US6765012B2
(en)
|
2001-09-27 |
2004-07-20 |
Allergan, Inc. |
3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
US7005444B2
(en)
|
2001-09-27 |
2006-02-28 |
Allergan, Inc. |
3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
|
BR0213185A
(pt)
|
2001-10-10 |
2004-09-14 |
Sugen Inc |
Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
DK1450811T3
(da)
*
|
2001-11-30 |
2010-02-15 |
Osi Pharm Inc |
Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
|
CN1816551A
(zh)
*
|
2001-12-20 |
2006-08-09 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
|
EA011809B1
(ru)
|
2001-12-20 |
2009-06-30 |
Оси Фармасьютикалз, Инк. |
Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения
|
ES2333702T3
(es)
|
2001-12-24 |
2010-02-26 |
Astrazeneca Ab |
Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
|
EA007395B3
(ru)
|
2002-01-22 |
2018-02-28 |
Уорнер-Ламберт Компани Ллс |
2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ
|
KR101093345B1
(ko)
|
2002-02-01 |
2011-12-14 |
아스트라제네카 아베 |
퀴나졸린 화합물
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
AU2003208479A1
(en)
|
2002-03-09 |
2003-09-22 |
Astrazeneca Ab |
4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
|
US7271266B2
(en)
|
2002-03-28 |
2007-09-18 |
Merck & Co., Inc. |
Substituted 2,3-diphenyl pyridines
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
US6541504B1
(en)
|
2002-04-03 |
2003-04-01 |
Allergan Sales, Llc |
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
PL373339A1
(en)
*
|
2002-04-19 |
2005-08-22 |
Smithkline Beecham Corporation |
Novel compounds
|
CN100396670C
(zh)
*
|
2002-05-15 |
2008-06-25 |
詹森药业有限公司 |
作为pdfg受体抑制剂的n-取代的3-氨基苯并环戊二烯并吡唑及药用组合物和用途
|
EP1528925B1
(de)
*
|
2002-07-09 |
2009-04-22 |
Astrazeneca AB |
Chinazoline derivative und ihre anwendung in der krebsbehandlung
|
GB0215823D0
(en)
*
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
MXPA05000950A
(es)
|
2002-07-25 |
2005-05-16 |
Pfizer Prod Inc |
Derivados de isotiazol utiles como agentes anticancerosos.
|
CA2494061C
(en)
*
|
2002-07-31 |
2011-06-14 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
US8450302B2
(en)
|
2002-08-02 |
2013-05-28 |
Ab Science |
2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
|
DK1525200T3
(da)
|
2002-08-02 |
2007-12-03 |
Ab Science |
2-(3-aminoaryl)amino-4-aryl-thiazoler til sygdomsbehandling
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
CA2496164C
(en)
|
2002-08-23 |
2010-11-09 |
Chiron Corporation |
Benzimidazole quinolinones and uses thereof
|
ATE380810T1
(de)
*
|
2002-10-09 |
2007-12-15 |
Critical Outcome Technologies |
Protein-tyrosine-kinase-inhibitoren
|
GB0225548D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Compounds
|
GB0225579D0
(en)
*
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
WO2004041829A1
(en)
|
2002-11-04 |
2004-05-21 |
Astrazeneca Ab |
Quinazoline derivatives as src tyrosine kinase inhibitors
|
MXPA05004328A
(es)
*
|
2002-11-04 |
2005-08-02 |
Nps Pharma Inc |
Compuestos de quinazolinona como calciliticos.
|
AU2003275939A1
(en)
*
|
2002-11-08 |
2004-06-07 |
Novo Nordisk A/S |
Safe chemical uncouplers for the treatment of obesity
|
JP2006511616A
(ja)
|
2002-11-13 |
2006-04-06 |
カイロン コーポレイション |
癌の処置方法およびその関連方法
|
US6699863B1
(en)
|
2002-11-27 |
2004-03-02 |
Allergan, Inc. |
Kinase inhibitors for the treatment of disease
|
US6747025B1
(en)
|
2002-11-27 |
2004-06-08 |
Allergan, Inc. |
Kinase inhibitors for the treatment of disease
|
PT1625121E
(pt)
|
2002-12-20 |
2010-03-11 |
Pfizer Prod Inc |
Derivados de piridina para o tratamento de crescimento celular anormal
|
UA83814C2
(ru)
|
2002-12-24 |
2008-08-26 |
Астразенека Аб |
Производные фосфонооксихиназолина и их фармацевтическое применение
|
JP2006517976A
(ja)
*
|
2003-02-14 |
2006-08-03 |
スミスクライン・ビーチャム・コーポレイション |
新規化合物
|
DK1603570T5
(da)
|
2003-02-26 |
2013-12-09 |
Sugen Inc |
Aminoheteroarylforbindelser som proteinkinaseinhibitorer
|
US7157577B2
(en)
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
DK1631295T3
(da)
|
2003-06-06 |
2010-06-21 |
Arexis Ab |
Anvendelse af kondenserede heterocykliske forbindelser som SCCE-inhibitorer ved behandling af hudsygdomme
|
WO2005003100A2
(en)
*
|
2003-07-03 |
2005-01-13 |
Myriad Genetics, Inc. |
4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
WO2005016875A2
(en)
|
2003-08-06 |
2005-02-24 |
Sugen, Inc. |
Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
|
AU2004268614C1
(en)
|
2003-08-27 |
2010-10-28 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
SI1667991T1
(sl)
|
2003-09-16 |
2008-10-31 |
Astrazeneca Ab |
Kinazolinski derivati kot inhibitorji tirozin kinaze
|
WO2005028469A1
(en)
|
2003-09-19 |
2005-03-31 |
Astrazeneca Ab |
Quinazoline derivatives
|
CA2549579A1
(en)
*
|
2003-10-07 |
2005-04-28 |
Centelion |
Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
|
US7718676B2
(en)
|
2003-10-23 |
2010-05-18 |
Ab Science |
2-aminoaryloxazole compounds as tyrosine kinase inhibitors
|
WO2005044788A1
(ja)
|
2003-11-11 |
2005-05-19 |
Eisai Co., Ltd. |
ウレア誘導体およびその製造方法
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP2007511514A
(ja)
*
|
2003-11-13 |
2007-05-10 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
生体分子標的同定用の固定化n置換三環状3−アミノピラゾール
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
BRPI0400869B8
(pt)
*
|
2004-03-02 |
2021-05-25 |
Univ Estadual Campinas Unicamp |
novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
|
BRPI0507891A
(pt)
|
2004-02-20 |
2007-07-24 |
Chiron Corp |
modulação dos processos inflamatório e metastático
|
MXPA06011423A
(es)
|
2004-04-02 |
2007-01-23 |
Osi Pharm Inc |
Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
|
WO2005118587A1
(en)
*
|
2004-06-02 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Indole derivative and use for treatment of cancer
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
AU2005283422C1
(en)
|
2004-09-17 |
2017-02-02 |
Eisai R & D Management Co., Ltd. |
Medicinal composition
|
US20070197538A1
(en)
*
|
2004-10-07 |
2007-08-23 |
Mark Nesbit |
Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
|
CA2581516C
(en)
|
2004-10-12 |
2013-06-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2006045010A2
(en)
*
|
2004-10-20 |
2006-04-27 |
Resverlogix Corp. |
Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
|
CN101124228B
(zh)
|
2004-12-14 |
2011-06-15 |
阿斯利康(瑞典)有限公司 |
用作抗肿瘤药物的吡唑并嘧啶化合物
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
WO2006090717A1
(ja)
|
2005-02-23 |
2006-08-31 |
Shionogi & Co., Ltd. |
チロシンキナーゼ阻害作用を有するキナゾリン誘導体
|
AU2006217738A1
(en)
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
WO2006094034A1
(en)
|
2005-03-01 |
2006-09-08 |
Wyeth |
Cinnoline compounds and their use as liver x receptor modilators
|
EP1868612A4
(de)
*
|
2005-03-25 |
2010-03-24 |
Glaxo Group Ltd |
Neuartige verbindungen
|
UY29440A1
(es)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
PE20061193A1
(es)
*
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
|
MX2007012951A
(es)
*
|
2005-03-25 |
2008-01-11 |
Glaxo Group Ltd |
Procedimiento para preparar derivados de pirido[2,3-d] pirimidin-7-ona y 3,4-dihidropirimidino[4,5-d]pirimidin-2(1h)-ona.
|
JP5204643B2
(ja)
|
2005-04-04 |
2013-06-05 |
アブ サイエンス |
置換オキサゾール誘導体、およびチロシンキナーゼ阻害薬としてのそれらの使用
|
EP2591784B1
(de)
|
2005-05-10 |
2016-09-14 |
Intermune, Inc. |
Pyridin-2-on-Derivate als Modulatoren des Stress-aktivierten Proteinkinase Systems
|
EP1885187B1
(de)
|
2005-05-13 |
2013-09-25 |
Novartis AG |
Verfahren zur behandlung von arzneimittelresistentem krebs
|
EP1888556B1
(de)
|
2005-05-17 |
2011-10-26 |
Novartis AG |
Verfahren zur synthese heterocyclischer verbindungen
|
BRPI0611375A2
(pt)
|
2005-05-23 |
2010-08-31 |
Novartis Ag |
formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
|
EP2314295B1
(de)
|
2005-07-29 |
2015-01-28 |
Resverlogix, Inc |
Arzneimittel zur Prävention und Behandlung komplexer Erkrankungen und deren Freisetzung mittels einsetzbarer Medizinprodukte
|
EP1925676A4
(de)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
Testverfahren für die wirkung eines vaskularisierungsinhibitors
|
WO2007028051A2
(en)
|
2005-09-02 |
2007-03-08 |
Abbott Laboratories |
Novel imidazo based heterocycles
|
EP1928861B1
(de)
|
2005-09-20 |
2010-11-17 |
AstraZeneca AB |
4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
|
US20080003219A1
(en)
*
|
2005-09-26 |
2008-01-03 |
Minu, L.L.C. |
Delivery of an ocular agent
|
EP1934213A1
(de)
|
2005-09-30 |
2008-06-25 |
Astra Zeneca AB |
Imidazo [1,2-a] pyridin mit antizellproliferationswirkung
|
GB0519879D0
(en)
|
2005-09-30 |
2005-11-09 |
Astrazeneca Ab |
Chemical process
|
AR057960A1
(es)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
AU2006327300A1
(en)
|
2005-12-20 |
2007-06-28 |
Astrazeneca Ab |
Substituted Cinnoline derivatives as GABAa-receptor modulators and method for their synthesis
|
US7465795B2
(en)
|
2005-12-20 |
2008-12-16 |
Astrazeneca Ab |
Compounds and uses thereof
|
US8338415B2
(en)
|
2006-01-24 |
2012-12-25 |
Allergan, Inc. |
Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
|
UY30183A1
(es)
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
Derivados de quinolina
|
US7977351B2
(en)
|
2006-03-22 |
2011-07-12 |
Allergan, Inc. |
Heteroaryl dihydroindolones as kinase inhibitors
|
UA91129C2
(ru)
|
2006-05-09 |
2010-06-25 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
|
CN101443009A
(zh)
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
CN101100466B
(zh)
|
2006-07-05 |
2013-12-25 |
天津和美生物技术有限公司 |
不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
|
US8246966B2
(en)
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
EP2065372B1
(de)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumormittel gegen undifferenzierten magenkrebs
|
KR101129868B1
(ko)
*
|
2006-10-04 |
2012-04-12 |
화이자 프로덕츠 인코포레이티드 |
칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
US8558002B2
(en)
|
2006-11-16 |
2013-10-15 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
WO2008061236A2
(en)
|
2006-11-16 |
2008-05-22 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
EP2088863A2
(de)
|
2006-11-22 |
2009-08-19 |
University Of Georgia Research Foundation, Inc. |
Tyrosinkinase-hemmer als antikinetolastid- und anti-sporentierchen-wirkstoffe
|
US8034815B2
(en)
|
2007-01-11 |
2011-10-11 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
WO2008093855A1
(ja)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
PL2118074T3
(pl)
|
2007-02-01 |
2014-06-30 |
Resverlogix Corp |
Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
|
AU2008212999A1
(en)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
WO2008127199A1
(en)
|
2007-04-13 |
2008-10-23 |
Agency For Science, Technology And Research |
Methods of controlling tumorigenesis and diagnosing the risk thereof
|
BRPI0810411B8
(pt)
|
2007-04-18 |
2021-05-25 |
Pfizer Prod Inc |
derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
|
EP2150255A4
(de)
*
|
2007-05-10 |
2011-10-05 |
Glaxosmithkline Llc |
Chinoxalinderivate als p13-kinase-inhibitoren
|
ES2569483T3
(es)
|
2007-06-21 |
2016-05-11 |
Amgen Inc. |
Métodos para sintetizar cinacalcet y sales del mismo
|
WO2009057139A2
(en)
|
2007-10-29 |
2009-05-07 |
Natco Pharma Limited |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
US8969313B2
(en)
|
2007-11-02 |
2015-03-03 |
Agency For Science, Technology And Research |
Methods and compounds for preventing and treating a tumour
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
WO2009079797A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
KR101653842B1
(ko)
|
2008-01-04 |
2016-09-02 |
인텔리카인, 엘엘씨 |
특정 화학 물질, 조성물 및 방법
|
EP2245026B1
(de)
|
2008-02-07 |
2012-08-01 |
Boehringer Ingelheim International GmbH |
Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
NZ589883A
(en)
|
2008-05-13 |
2012-06-29 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
|
CA2726588C
(en)
|
2008-06-03 |
2019-04-16 |
Karl Kossen |
Compounds and methods for treating inflammatory and fibrotic disorders
|
CN101970416B
(zh)
|
2008-06-26 |
2014-05-28 |
雷斯韦洛吉克斯公司 |
制备喹唑啉酮衍生物的方法
|
EP3023426A1
(de)
|
2008-07-17 |
2016-05-25 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren
|
US8648191B2
(en)
|
2008-08-08 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
EP3924343A1
(de)
|
2008-09-26 |
2021-12-22 |
Merck Sharp & Dohme Corp. |
Neue, cyclische benzimidazolderivate, die sich als antidiabetische mittel eignen
|
MX2011004258A
(es)
|
2008-10-22 |
2011-06-01 |
Merck Sharp & Dohme |
Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
|
AU2009309007A1
(en)
|
2008-10-29 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
EP2349235A1
(de)
|
2008-11-07 |
2011-08-03 |
Triact Therapeutics, Inc. |
Verwendung von catecholbutan-derivaten in der krebstherapie
|
NZ594332A
(en)
|
2009-01-08 |
2013-09-27 |
Resverlogix Corp |
Compounds for the prevention and treatment of cardiovascular disease
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
|
EP2401614A1
(de)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2408479A1
(de)
|
2009-03-18 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Kombinationskrebstherapie mit verabreichung eines egfr-hemmers und eines igf-1r-hemmers
|
AU2010224523B2
(en)
|
2009-03-18 |
2014-05-08 |
Resverlogix Corp. |
Novel anti-inflammatory agents
|
LT2421533T
(lt)
*
|
2009-04-22 |
2018-12-27 |
Resverlogix Corp. |
Nauji priešuždegiminiai agentai
|
SG176628A1
(en)
|
2009-06-05 |
2012-01-30 |
Link Medicine Corp |
Aminopyrrolidinone derivatives and uses thereof
|
EP2473500A2
(de)
|
2009-09-01 |
2012-07-11 |
Pfizer Inc. |
Benzimidazolderivate
|
MX2012002596A
(es)
|
2009-09-03 |
2012-07-03 |
Allergan Inc |
Compuestos como moduladores de tirosina cinasas.
|
US9340555B2
(en)
|
2009-09-03 |
2016-05-17 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
EP2510110A1
(de)
|
2009-11-13 |
2012-10-17 |
Pangaea Biotech S.L. |
Molekulare biomarker zur vorhersage der reaktion auf tyrosinkinaseinhibitoren bei lungenkrebs
|
EP2538784B1
(de)
|
2010-02-25 |
2015-09-09 |
Merck Sharp & Dohme Corp. |
Benzimidazolderivate als antidiabetika
|
CA2794952C
(en)
|
2010-04-01 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
WO2011153049A1
(en)
|
2010-06-02 |
2011-12-08 |
The Trustees Of The University Of Pennsylvania |
Methods and use of compounds that bind to her2/neu receptor complex
|
US9265739B2
(en)
|
2010-06-02 |
2016-02-23 |
The Trustees Of The University Of Pennsylvania |
Methods and use of compounds that bind to HER2/neu receptor complex
|
ES2685171T3
(es)
|
2010-06-14 |
2018-10-05 |
The Scripps Research Institute |
Reprogramación de células a un nuevo destino
|
ES2573515T3
(es)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
|
EP2593452B1
(de)
|
2010-07-14 |
2017-01-18 |
Novartis AG |
Heterocyclische verbindungen als ip-rezeptoragonisten
|
US9056865B2
(en)
|
2010-10-20 |
2015-06-16 |
Pfizer Inc. |
Pyridine-2-derivatives as smoothened receptor modulators
|
EP2468883A1
(de)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
|
CA2824197C
(en)
|
2011-01-10 |
2020-02-25 |
Michael Martin |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
EP2492688A1
(de)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
RU2580609C2
(ru)
|
2011-04-18 |
2016-04-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
EP2702173A1
(de)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Verwendung von emt-gensignaturen bei der entdeckung von krebswirkstoffen, -diagnostika und -behandlungen
|
ES2841809T3
(es)
|
2011-06-03 |
2021-07-09 |
Eisai R&D Man Co Ltd |
Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
JP5913588B2
(ja)
*
|
2011-06-30 |
2016-04-27 |
ダウ グローバル テクノロジーズ エルエルシー |
ビフェノールエーテル化合物
|
KR20140057356A
(ko)
|
2011-08-31 |
2014-05-12 |
제넨테크, 인크. |
진단 마커
|
CN103814030A
(zh)
|
2011-09-22 |
2014-05-21 |
辉瑞大药厂 |
吡咯并嘧啶及嘌呤衍生物
|
WO2013055530A1
(en)
|
2011-09-30 |
2013-04-18 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
|
US9610251B2
(en)
|
2011-11-01 |
2017-04-04 |
Resverlogix Corp. |
Pharmaceutical compositions for substituted quinazolinones
|
CN104053659B
(zh)
|
2012-01-13 |
2016-11-09 |
诺华股份有限公司 |
用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
EP2890706A1
(de)
|
2012-08-31 |
2015-07-08 |
Westfälische Wilhelms-Universität Münster |
Verfahren und peptide zur vorbeugung und behandlung von mit bcr-abl und c-abl assoziierten krankheiten
|
AR092742A1
(es)
|
2012-10-02 |
2015-04-29 |
Intermune Inc |
Piridinonas antifibroticas
|
SG11201502369XA
(en)
|
2012-10-16 |
2015-05-28 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of ror-gamma-t
|
AU2013331505A1
(en)
|
2012-10-16 |
2015-04-30 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of ROR-gamma-t
|
KR20150070348A
(ko)
|
2012-10-16 |
2015-06-24 |
얀센 파마슈티카 엔.브이. |
RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
|
WO2014080291A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Biaryl derivatives as bromodomain inhibitors
|
WO2014080290A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Cyclic amines as bromodomain inhibitors
|
CN105073744B
(zh)
|
2012-12-21 |
2019-11-08 |
齐尼思表观遗传学有限公司 |
作为溴结构域抑制剂的新型杂环化合物
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
EP2956455B1
(de)
|
2013-02-13 |
2017-05-17 |
Novartis AG |
Als ip-rezeptor-agonisten wirkende heterocyclische verbindungen
|
AU2014223548A1
(en)
|
2013-02-26 |
2015-10-15 |
Triact Therapeutics, Inc. |
Cancer therapy
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
EP3044593A4
(de)
|
2013-09-09 |
2017-05-17 |
Triact Therapeutics, Inc. |
Krebstherapie
|
MX370490B
(es)
|
2013-09-16 |
2019-12-16 |
Astrazeneca Ab |
Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
|
BR112016007467B1
(pt)
|
2013-10-04 |
2022-09-20 |
Infinity Pharmaceuticals, Inc |
Compostos heterocíclicos e usos dos mesmos
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
WO2015057626A1
(en)
|
2013-10-15 |
2015-04-23 |
Janssen Pharmaceutica Nv |
QUINOLINYL MODULATORS OF RORyT
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
JP6423423B2
(ja)
*
|
2013-10-15 |
2018-11-14 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Rorγtのアルキル結合キノリニルモジュレーター
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
CN113620958A
(zh)
|
2014-03-19 |
2021-11-09 |
无限药品股份有限公司 |
用于治疗PI3K-γ介导的障碍的杂环化合物
|
MX2016012808A
(es)
|
2014-04-02 |
2017-01-05 |
Intermune Inc |
Piridinonas anti-fibroticas.
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
BR112016024513A2
(pt)
|
2014-04-30 |
2017-08-15 |
Pfizer |
derivados de di-heterociclo ligados à cicloalquila
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
HRP20221047T1
(hr)
|
2014-08-28 |
2022-11-11 |
Eisai R&D Management Co., Ltd. |
Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
EP3216783B1
(de)
*
|
2014-11-07 |
2021-06-09 |
San-Apro Ltd. |
Sulfonatverbindung, fotosäuregenerator und fotolithografische harzzusammensetzung
|
RU2739942C2
(ru)
|
2014-12-24 |
2020-12-30 |
Дженентек, Инк. |
Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
|
MX2017010230A
(es)
|
2015-02-11 |
2017-12-04 |
Basilea Pharm Int Ag |
Derivados de mono- y poliazanaftaleno sustituidos y su uso.
|
FI3263106T3
(fi)
|
2015-02-25 |
2024-01-03 |
Eisai R&D Man Co Ltd |
Menetelmä kinoliinijohdannaisen kitkeryyden tukahduttamiseksi
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
US10111885B2
(en)
|
2015-03-13 |
2018-10-30 |
Resverlogix Corp. |
Compositions and therapeutic methods for the treatment of complement-associated diseases
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
EP3317323B1
(de)
|
2015-07-01 |
2021-05-26 |
California Institute of Technology |
Kationische schleimsäurepolymerbasierte abgabesysteme
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
CA2998469A1
(en)
|
2015-09-14 |
2017-03-23 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
EP3390364B1
(de)
|
2015-12-17 |
2020-07-15 |
Biokine Therapeutics Ltd. |
Kleine moleküle zur hemmung der chemokinaktivität und/oder des wachstums von krebzellen
|
WO2017103931A1
(en)
|
2015-12-17 |
2017-06-22 |
Biokine Therapeutics Ltd. |
Small molecules against cancer
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US11147818B2
(en)
|
2016-06-24 |
2021-10-19 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
DK3484528T3
(da)
|
2016-07-18 |
2021-02-15 |
Janssen Pharmaceutica Nv |
Tau-pet-billeddannelsesligander
|
ES2894255T3
(es)
|
2016-12-22 |
2022-02-14 |
Amgen Inc |
Derivados de benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibidores de KRAS G12C para tratar el cáncer de pulmón, pancreático o colorrectal
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
WO2019213516A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3788053A1
(de)
|
2018-05-04 |
2021-03-10 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
AU2019284472A1
(en)
|
2018-06-11 |
2020-11-26 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
EP3807276A2
(de)
|
2018-06-12 |
2021-04-21 |
Amgen Inc. |
Einen piperazinring umfassende kras g12c-inhibitoren und ihre verwendung zur krebsbehandlung
|
AU2019352741A1
(en)
|
2018-10-04 |
2021-05-06 |
Assistance Publique-Hôpitaux De Paris (Aphp) |
EGFR inhibitors for treating keratodermas
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
EP3883565A1
(de)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
AU2019404576A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
JP2022513971A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
JP7407196B2
(ja)
|
2018-12-20 |
2023-12-28 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
CN109776413A
(zh)
*
|
2019-01-29 |
2019-05-21 |
天津科技大学 |
一种具有降糖活性的异喹啉衍生物和应用
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
SG11202109422WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heterocyclyl compounds and uses thereof
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
KR20220009442A
(ko)
|
2019-05-15 |
2022-01-24 |
아론바이오 리미티드 |
암 치료, 케모카인 활성 억제 및/또는 세포사 유도를 위한 소분자
|
AU2020280024A1
(en)
|
2019-05-21 |
2021-12-09 |
Amgen Inc. |
Solid state forms
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
EP4007756A1
(de)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a-inhibitoren
|
AU2020326627A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
CA3155857A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
BR112022008534A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
CN116425742A
(zh)
|
2019-11-08 |
2023-07-14 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
AR120457A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
EP4058432A1
(de)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Verbesserte synthese einer kras-g12c-hemmenden verbindung
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
CN114929279A
(zh)
|
2020-01-07 |
2022-08-19 |
锐新医药公司 |
Shp2抑制剂给药和治疗癌症的方法
|
MX2022016355A
(es)
|
2020-06-18 |
2023-04-03 |
Revolution Medicines Inc |
Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
|
AU2021320254A1
(en)
|
2020-08-07 |
2023-03-02 |
Athos Therapeutics, Inc. |
Small molecules for the treatment of autoimmune diseases and cancer
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
WO2022060836A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Indole derivatives as ras inhibitors in the treatment of cancer
|
CN112047882A
(zh)
*
|
2020-10-15 |
2020-12-08 |
天津科技大学 |
一种异喹啉和喹啉衍生物用于制备降血脂药物方面中的新应用
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
IL305165A
(en)
|
2021-02-19 |
2023-10-01 |
Sudo Biosciences Ltd |
TYK2 inhibitors and their uses
|
EP4334324A1
(de)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Kovalente ras-inhibitoren und verwendungen davon
|
KR20240004960A
(ko)
|
2021-05-05 |
2024-01-11 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|